The company expects to conduct a capital raise that, along with the expected (and recent) exercise of outstanding warrants, could extend its cash runway significantly. Additionally, AEMD has made cost reductions and also stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia and lower costs of conducting clinical trials in India. Separately, while the company's near-term focus is on assessing the Hemopurifier as a potential treatment for oncology, longer-term AEMD continues to view the device as a potential tool in the treatment of viruses, organ transplants and other medical areas. The company will continue to monitor the situation with bird flu in case the need for treatment with the device arises.
